Saturday 17 October 2026
Export GRDN’s income statement to Excel — free account
Guardian Pharmacy Services, Inc.
GRDN Healthcare Medical Care Facilities
Guardian Pharmacy Services, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.4 billion, up 17.9% from fiscal 2024. In the quarter to June 2026, revenue grew 2.16%, EPS grew 133.3% and free cash flow grew 60.8%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
39.41
0.27
−0.68%
Follow GRDN
| Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|
Piotroski F-Score |
— | — | 7 |
P/E ratio |
0.00 | 0.00 | 38.09 |
P/S ratio |
0.00 | 1.02 | 1.30 |
Altman Z-Score |
— | 7.70 | 10.28 |
P/FCF ratio |
0.00 | 30.20 | 23.26 |
Altman Z″-Score (non-manufacturers) |
— | (0.06) | 3.85 |
Beneish M-Score |
— | (4.15) | (2.95) |
P/Operating CF |
0.00 | 56.24 | 54.25 |
P/B ratio |
0.00 | 8.38 | 8.61 |
Price to Tangible BV |
0.00 | 19.10 | 15.68 |
EV/Sales |
0.00 | 1.05 | 1.28 |
EV/EBITDA |
0.00 | 0.00 | 19.47 |
EV/Operating CF |
0.00 | 22.26 | 18.46 |
EV/FCF |
0.00 | 31.02 | 22.92 |
Quick Ratio |
0.57 | 0.71 | 1.04 |
Current Ratio |
0.94 | 1.05 | 1.38 |
Net Debt/EBITDA |
0.46 | 0.11 | (0.69) |
Debt/Assets |
10.32% | 0.00% | 0.00% |
Debt/Equity |
0.47 | 0.00 | 0.00 |
Asset Turnover |
0.00 | 4.15 | 3.95 |
Operating CF/Net income |
0.00 | (0.53) | 2.04 |
Capex/Depreciation |
(0.80) | (0.83) | (0.88) |
Interest Coverage |
14.32 | (19.19) | 109.33 |
| — | (104.89%) | 26.76% | |
| — | (37.18%) | 13.42% | |
ROIC |
29.38% | (27.06%) | 29.83% |
Return on Tangible Assets |
0.00% | (190.57%) | 42.27% |
Average Days of Receivables |
26.96 | 28.87 | 25.60 |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
16.00% | 25.02% | 15.19% |
Intangible Assets out of Total Assets |
0.25 | 0.26 | 0.24 |
Share Based Compensation of Revenue |
(0.58%) | 10.70% | 0.96% |
Graham Net Nets |
0.00 | (0.01) | 0.01 |
Graham Number |
0.00 | 0.00 | 7.88 |
Earnings Yield |
(7.09%) | (7.09%) | 2.63% |
Free Cash Flow Yield |
0.00% | 3.31% | 4.30% |
Revenue per Share |
0.00 | 19.81 | 23.22 |
Operating CF per Share |
0.00 | 0.93 | 1.61 |
Capex per Share |
0.00 | (0.26) | (0.31) |
Free Cash Flow per Share |
0.00 | 0.67 | 1.29 |
Cash per Share |
0.00 | 0.08 | 1.05 |
Shareholders Equity per Share |
0.00 | 2.42 | 3.49 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 |
Book value per Share |
0.00 | 2.42 | 3.49 |
Free Cash Flow |
56.26 | 41.59 | 80.71 |
Working Capital |
(8.41) | 7.86 | 60.93 |
Capital Expenditures |
(14.56) | (16.37) | (19.54) |
Net Current Asset Value |
(81.70) | (18.85) | 26.90 |
EV/EBIT |
0.00 | 0.00 | 25.45 |
Capex to Sales |
0.01 | 0.01 | 0.01 |
Price to Operating Income |
0.00 | 0.00 | 25.82 |
| Other line items | |||
Depreciation/Fixed assets |
0.40 | 0.40 | 0.40 |
Cash ROIC |
63.50% | 26.90% | 28.46% |
Accounts Receivable Turnover |
0.00 | 14.09 | 14.58 |
Accounts Payable Turnover |
0.00 | 10.47 | 10.57 |
Inventory Turnover |
0.00 | 25.47 | 27.55 |
Average Days of Payables |
37.29 | 37.99 | 36.69 |
Days of Inventory on Hand |
16.00 | 15.04 | 13.69 |
Average Receivables |
— | 87.21 | 99.38 |
Average Payables |
— | 94.01 | 109.31 |
Average Inventory |
— | 38.64 | 41.95 |
Average Assets |
— | 295.99 | 366.73 |
Average Common Equity |
— | 104.92 | 183.95 |
Columns are period end dates